Core Viewpoint - The flu vaccine is considered the "first line of defense" against influenza, significantly reducing the risk of infection and severe complications, yet its uptake in China remains low, hovering in single digits compared to the more successful flu treatment drug market [1] Group 1: Market Performance - In 2024, the sales figures for flu vaccine companies in A-shares and Hong Kong include: Hualan Vaccine at 1.073 billion yuan, Jindike at 80.827 million yuan, and Zhonghui Biological at 260 million yuan [2] - The total sales for the four major flu vaccine companies, including Baike Biological, are projected to be under 1.6 billion yuan, which is significantly lower than the 2.6 billion yuan sales of the flu treatment drug Oseltamivir by Dongyangguang Pharmaceutical [3] Group 2: Economic Burden and Benefits - The economic burden of influenza for outpatient patients ranges from 801 to 1,320 yuan, while for hospitalized patients, it can be between 9,832 and 23,833 yuan, indicating that flu vaccination can effectively reduce related medical costs and improve economic outcomes [3] Group 3: Challenges in Vaccine Promotion - Public misconceptions about the necessity and effectiveness of the flu vaccine, as well as concerns over side effects, hinder its promotion and uptake [5] - Vaccine hesitancy, recognized as a global health threat, leads to underestimation of the flu's severity and a lack of understanding of vaccine efficacy, impacting vaccination rates [6] - To improve vaccination rates, it is essential to enhance public education, increase accessibility to vaccination services, and develop better funding mechanisms for vaccine costs [6]

证券日报网讯 11月26日晚间，金迪克发布公告称，公司股票连续2个交易日内（2025年11月25日、2025 年11月26日）收盘价格涨幅偏离值累计达到30%，属于股票交易异常波动。经公司自查，并发函询证控 股股东、实际控制人，截至本公告披露日，公司不存在应披露而未披露的重大信息。公司目前生产经营 正常，未发生重大变化。 （编辑 姚尧） ...

Group 1 - The Ministry of Industry and Information Technology and five other departments issued a plan to enhance the adaptability of supply and demand for consumer goods, aiming for a significant optimization of the supply structure by 2027, with the formation of three trillion-level consumption fields and ten hundred-billion-level consumption hotspots [2] - The State Council Information Office will hold a press conference on November 27, 2025, to discuss policies related to enhancing the adaptability of supply and demand for consumer goods [2] - The National Development and Reform Commission will hold a news conference on November 27, 2025, to provide updates on relevant policies [2] Group 2 - Guangdong issued a plan to support enterprises in conducting industrial chain integration and mergers, aiming to enhance the competitive advantages of industrial clusters in the Guangdong-Hong Kong-Macao Greater Bay Area by 2027 [3] - The China Insurance Industry Association issued a risk warning regarding "Anwo Stock Insurance," clarifying that it is not an approved insurance institution and that stock investment losses are not covered by insurance [3] Group 3 - Changguang Huaxin has achieved mass production of 100G EML in the optical communication field, and 200G EML has begun sampling [5] - Shida Group noted that it has not engaged in business cooperation with Alibaba Cloud despite market rumors [6] - Jindike will not issue new quadrivalent influenza virus split vaccines this year [7] - Zhongshui Fishery reported no significant changes in its operating conditions and external environment [8] - Maoye Commercial is currently operating normally [9] - Industrial Fulian raised the upper limit for share repurchase to no more than 75 yuan per share [10] - China Iron and Steel's controlling shareholder plans to increase its stake in the company by 65 million to 130 million yuan [11] - Boda Pharmaceutical has not organized the production and sale of related influenza drugs, and it is expected that there will be no impact on the company's operating performance for a considerable period [11] - Muxi Co., Ltd. announced that the subscription date for its issuance is December 5 [11] - Pinming Technology may apply for a trading suspension if its stock continues to experience abnormal fluctuations [12]

金迪克表示，截至公告披露日，公司本年度生产季已经结束，取得批签发证明的四价流感病毒裂解疫苗 共约156万支，本年度内不会新增四价流感病毒裂解疫苗批签发。公司客户主要为国内各地疾控中心， 产品销售受流感季节性波动以及市场推广等因素影响，能否全部实现销售存在一定的不确定性。 北京商报讯（记者 丁宁）11月26日晚间，金迪克（688670）发布股票交易异常波动公告显示，公司股 票连续2个交易日内收盘价格涨幅偏离值累计达到30%，根据《上海证券交易所交易规则》《上海证券 交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动。 ...

Market Overview - A total of 68 stocks hit the daily limit up, while 23 stocks faced limit down, resulting in a sealing rate of 75% [1] - The Shenzhen Component Index and the ChiNext Index opened lower but rebounded, with the ChiNext Index at one point rising over 3% [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.78 trillion, a decrease of 28.8 billion from the previous trading day [1] - The market saw rapid rotation of hotspots, with over 3,500 stocks declining [1] - The Shanghai Composite Index fell by 0.15%, while the Shenzhen Component Index rose by 1.02%, and the ChiNext Index increased by 2.14% [1] Stock Performance Analysis - The consecutive board advancement rate increased to 58.33%, maintaining a peak of 5 boards [3] - Notable stocks included Shida Group with 5 consecutive boards, Huayi Century, TeFa Information, and Xinhua Du with 4 consecutive boards, and Guangji Pharmaceutical, Leike Defense, and Jinfu Technology with 3 consecutive boards [3][4] - The AI application sector saw strong performance, with Shida Group and Xinhua Du achieving board advancement, while previously strong stocks like Rongji Software faced a limit down [3] Sector Highlights - The pharmaceutical, retail, and CPO sectors showed significant gains, while military equipment, forestry, and gaming sectors experienced declines [1] - The anti-influenza and consumer sectors were driven by news, but overall performance remained primarily a technical correction following previous declines [3] - The demand for flu-related medications and online consultations surged, with orders for specific flu medications increasing over 100% compared to the previous month [7][13] AI and Technology Sector - Google is collaborating with Broadcom to develop TPU v7p, expected to launch in 2026, with a forecasted shipment increase of over 40% [5] - The computing hardware sector continues to gain momentum, with leading companies like Zhongji Xuchuang and Saiwei Electronics reaching historical highs [5] - The AI application sector remains reliant on major players like Alibaba, with ongoing interest in the AI application market expected to persist [6] Consumer Sector - The Ministry of Industry and Information Technology and other departments released a plan to enhance consumer goods supply and demand adaptability, stimulating the consumer sector [7][24] - Stocks in the retail sector, such as Guoguang Chain and Dongbai Group, saw significant gains following this policy announcement [7][24] Conclusion - The market is characterized by a mix of strong performances in specific sectors like AI and pharmaceuticals, while facing challenges in others like military and gaming [1][3][5] - The ongoing developments in technology and consumer policies are likely to shape market dynamics in the near term [6][7][24]

Market Overview - The market exhibited a fragmented low-volume trading pattern, with the Shanghai Composite Index slightly down by 0.15%, while the Shenzhen Component and ChiNext Index rose by 1.02% and 2.14% respectively. Approximately 3,600 stocks declined against over 1,600 that rose, with total trading volume reaching 1.7 trillion [1][3]. AI Hardware Sector - The AI hardware sector saw significant gains, with OCS continuing to strengthen and the CPO sector experiencing a collective rise. Key stocks such as Special Information and Zhongji Xuchuang hit new highs, while others like Saimicroelectronics and Yuxi Technology also saw substantial increases [4][6][7]. Consumer Sector - The consumer sector experienced a resurgence in the afternoon following the release of a plan by six departments aimed at enhancing the adaptability of consumer goods supply and demand. This plan anticipates the formation of three trillion-level consumption areas and ten billion-level consumption hotspots by 2027. Retail stocks like Dongbai Group and Sanjiang Shopping surged, with several stocks hitting the daily limit [9][10]. Shenzhen Local Stocks - Following the announcement of a financial support plan for enterprises in Guangdong, Shenzhen local stocks initially showed little reaction but later surged in the afternoon, led by stocks like Teli A and Shenhua A. The rally was partly driven by news regarding Vanke's debt situation and restructuring plans, which sparked interest in related local stocks [12][14][15][17]. Reader Culture - Reader Culture experienced a sudden surge of over 7% in the afternoon, closing with a 5.1% increase. The rise was attributed to heightened media attention surrounding figures like Luo Yonghao, suggesting that market movements may be influenced by social media trends rather than fundamental factors [20].

Group 1 - Aolide plans to raise no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, with net proceeds allocated to the production base project for OLED display core materials and to supplement working capital [1] - Wanbang's subsidiary has obtained a 10-year exclusive agency for sildenafil oral suspension, which is suitable for patients with swallowing difficulties [2] - Titan Technology and its affiliate plan to jointly invest in increasing capital for its subsidiary, Micro Detection, raising its registered capital from 10 million yuan to 50 million yuan [3] Group 2 - Jindike will not issue new batches of quadrivalent influenza virus split vaccine this year, having produced approximately 1.56 million doses [4] - Aladdin intends to purchase 35% equity of Youke for 61.25 million yuan, funded by its own or raised capital [5] - Gujia Home's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] Group 3 - Honghe Technology's application for a private placement of A-shares has been approved by the China Securities Regulatory Commission [9] - Guangdian Yuntong has won contracts totaling 308 million yuan for the construction of an artificial intelligence application pilot base [10] - Shanghai Mechanical plans to repurchase B-shares worth no more than 278 million yuan [11] Group 4 - Weiling Co. is planning a change of control, with shares representing 7.76% of the total being transferred [14] - Jiugang Hongxing intends to invest 200 million yuan to establish a wholly-owned subsidiary focusing on high-quality special steel materials [16] - Zhongjian Technology has submitted an application for H-share listing [17] Group 5 - Sainuo Medical has received registration approval for its coronary product in Pakistan [18] - Huafeng Aluminum plans to acquire 100% equity of Huafeng Puen for 100 million yuan [20] - Fuda Co. intends to establish a wholly-owned subsidiary with an investment of 30 million yuan [22] Group 6 - Su Yan Jingshen's application for a private placement of shares has been approved by the Shanghai Stock Exchange [24] - Zhongchuang Co. has set the inquiry transfer price at 25.75 yuan per share [25] - Jinpu Garden has had a lawsuit involving 26.557 million yuan accepted by the court [29] Group 7 - ICBC has approved the appointment of Zhao Guid as vice president [30] - Betta Pharmaceuticals has had its drug registration application for ensartinib accepted [32] - Times New Materials plans to invest 6 million euros to establish a wholly-owned subsidiary in Serbia [34] Group 8 - China State Construction has appointed Chen Yong as vice president [36] - Dayang Electric plans to invest 10 million yuan to establish an industrial fund [38] - Advanced Digital has appointed Liu Zhigang as deputy general manager [39] Group 9 - Tianqi Co. plans to transfer 7% equity of Youqi Intelligent for 130 million yuan [40] - Xinguo has submitted an application for H-share issuance and listing [42] - Jinhongshun's shareholder has terminated a share reduction plan [43] Group 10 - Wanrun Co.'s actual controller plans to increase shareholding between 365 million yuan and 730 million yuan [44] - Suzhou High-tech plans to sell 47% equity of its medical device subsidiary for 604 million yuan [45] - Huayou Cobalt's subsidiary has signed a product supply agreement with Yiwei Lithium Energy for approximately 127,800 tons of materials [47] Group 11 - China Communications has won 10 important projects totaling approximately 2.539 billion yuan [49] - Nopushin plans to raise no more than 1.45 billion yuan through a private placement [50] - Yun Aluminum plans to acquire minority stakes in three subsidiaries for a total of 2.267 billion yuan [51] Group 12 - Xiamen Tungsten plans to establish a 500 million yuan merger fund with multiple parties [52] - Aotewei has signed a contract worth approximately 700 million yuan [54] - Hemai Co.'s shareholders plan to reduce their holdings by no more than 3% [56]

Market Overview - The biopharmaceutical sector increased by 0.36% compared to the previous trading day, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Jindike (688670) saw a closing price of 30.90, with a significant increase of 20.00% and a trading volume of 192,400 shares, amounting to a transaction value of 572 million [1] - Rongchang Bio (688331) closed at 92.25, up 5.43%, with a trading volume of 68,800 shares and a transaction value of 635 million [1] - Sanofi (688336) closed at 68.39, up 4.59%, with a trading volume of 74,400 shares and a transaction value of 510 million [1] - Other notable performers include Olin Bio (616889) with a 4.43% increase and Hualan Bio (301207) with a 3.21% increase [1] Fund Flow Analysis - The biopharmaceutical sector experienced a net inflow of 20.94 million from institutional investors, while retail investors saw a net outflow of 57.02 million [2] - Jindike had a net inflow of 57.00 million from institutional investors, despite a net outflow of 19.76 million from retail investors [3] - Rongchang Bio also saw a net inflow of 32.94 million from institutional investors, with retail investors withdrawing 25.48 million [3]

公告称，截至本公告披露日，公司本年度生产季已经结束，取得批签发证明的四价流感病毒裂解疫苗共 约156万支，本年度内不会新增四价流感病毒裂解疫苗批签发。公司客户主要为国内各地疾控中心，产 品销售受流感季节性波动以及市场推广等因素影响，能否全部实现销售存在一定的不确定性。 金迪克(688670.SH)公告，公司股票连续2个交易日内(2025年11月25日、2025年11月26日)收盘价格涨幅 偏离值累计达到30%，属于股票交易异常波动。 ...

江苏金迪克生物技术股份有限公司 2025 年前三季度，公司营业收入 7,465.76 万元，同比增长 91.93%，归 属于上市公司股东的净利润-8,647.06 万元；归属于上市公司股东的扣除非经常 性损益的净利润-9,111.37 万元，处于亏损状态，预计 2025 年全年存在无法盈利 的 风 险 。 具 体 情 况 详 见 公 司 于 2025 年 10 月 25 日 在 上 海 证 券 交 易 所 （www.sse.com.cn）公告的《江苏金迪克生物技术股份有限公司 2025 年第三季 度报告》。 截至本公告披露日，公司本年度生产季已经结束，取得批签发证明的四 价流感病毒裂解疫苗共约 156 万支，本年度内不会新增四价流感病毒裂解疫苗 批签发。公司客户主要为国内各地疾控中心，产品销售受流感季节性波动以及 市场推广等因素影响，能否全部实现销售存在一定的不确定性。 证券代码：688670 证券简称：金迪克 公告编号：2025-036 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ...